v3.26.1
Supplemental Financial Information - Schedule of Foreign Exchange and Other Income/(Expense) (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2018
Derivative Instruments, Gain (Loss) [Line Items]          
Gain on sale of investment $ 13,648 $ 0 $ 13,648 $ 0  
Interest income 3,831 4,183 7,383 10,626  
FX fluctuations (779) (1,240) (1,368) (1,850)  
Impairment of investment 0 0 (1,132) 0  
Investment revaluation - Ceribell, Inc. 0 (1,008) 0 (3,622)  
Other 105 200 203 127  
Foreign exchange and other income/(expense) (23,829) $ (4,255) (29,524) 7,161  
Consideration receivable 17,100   17,058 $ 0  
Ceribell, Inc.          
Derivative Instruments, Gain (Loss) [Line Items]          
Number of shares issued in transactions (in shares)   391,952      
Average sales price (in dollars per share)   $ 16.69   $ 16.69  
Net proceeds   $ 6,500      
Equity method investment         $ 3,000
Balance Sheet Location [Axis]: us-gaap:OtherAssetsNoncurrent          
Derivative Instruments, Gain (Loss) [Line Items]          
Nontrade Receivables, Noncurrent 2,200   2,200    
Balance Sheet Location [Axis]: us-gaap:PrepaidExpenseAndOtherAssetsCurrent          
Derivative Instruments, Gain (Loss) [Line Items]          
Receivables from the sale of the investment 14,900   14,900    
2029 Embedded Derivative | 2029 Notes          
Derivative Instruments, Gain (Loss) [Line Items]          
Fair value adjustment (59,650) (10,867) (69,000) $ 3,726  
2029 Embedded Derivative | 2025 Notes          
Derivative Instruments, Gain (Loss) [Line Items]          
Fair value adjustment 0 (489) 0 1,552  
2029 Capped Calls | 2029 Notes          
Derivative Instruments, Gain (Loss) [Line Items]          
Fair value adjustment 19,016 4,468 20,742 (2,077)  
2029 Capped Calls | 2025 Notes          
Derivative Instruments, Gain (Loss) [Line Items]          
Fair value adjustment $ 0 $ 498 $ 0 $ (1,321)